University Hospital, Tours   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Tours France (1658)

Organization Overview

First Clinical Trial
2019
NCT03800524
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Centre d’Investigation Clinique 1415 | Centre Oncologie Radiothérapie 37 - CORT37 | CHRU DE TOURS | Dr Christophe LENCLUD | Hôpital Bretonneau - University Hospital of Tours | INSERM CIC-P 1415, University Hospital Center of Tours | Tours University Hospital | University Hospital of TOURS | University Hospital of TOURS;INSERM 1246 SPHERE | University Hospital, Tours

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Amyotrophic Lateral Sclerosis (Phase 3)

Cardiomyopathies (Phase 3)

Congenital Abnormalities (Phase 2)

Hemorrhage (Phase 3)

Hyperkalemia (Phase 4)

Lymphangioma (Phase 2)

Lymphatic Abnormalities (Phase 2)

Motor Neuron Disease (Phase 3)

Pneumonia (Phase 3)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Sclerosis (Phase 3)

Signs and Symptoms, Respiratory (Phase 3)

Subarachnoid Hemorrhage (Phase 3)

Vascular Malformations (Phase 2)

Ventricular Dysfunction, Left (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 21
  • # of Trial APIs: 22